Ann-Charlotte Hedling
Laboratory Technician at Department of Immunology, Genetics and Pathology; Research programme: Vascular Biology; Research group Lena Claesson Welsh
- E-mail:
- ann-charlotte.hedling@igp.uu.se
- Visiting address:
- Dag Hammarskjölds väg 20
751 85 Uppsala - Postal address:
- Rudbecklaboratoriet
751 85 UPPSALA
Publications
Recent publications
Part of Journal of Translational Medicine, 2023
- DOI for Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models
- Download full text (pdf) of Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models
Part of MOLECULAR THERAPY-ONCOLYTICS, p. 429-442, 2022
- DOI for Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition
- Download full text (pdf) of Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition
Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40
Part of Cancer Gene Therapy, p. 948-959, 2020
- DOI for Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40
- Download full text (pdf) of Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40
Immunostimulatory gene therapy enhances PD-1 blockade antibody therapy in experimental lung cancer
Part of CANCER IMMUNOLOGY RESEARCH, 2018
All publications
Articles in journal
Part of Journal of Translational Medicine, 2023
- DOI for Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models
- Download full text (pdf) of Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models
Part of MOLECULAR THERAPY-ONCOLYTICS, p. 429-442, 2022
- DOI for Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition
- Download full text (pdf) of Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition
Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40
Part of Cancer Gene Therapy, p. 948-959, 2020
- DOI for Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40
- Download full text (pdf) of Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40
Immunostimulatory gene therapy enhances PD-1 blockade antibody therapy in experimental lung cancer
Part of CANCER IMMUNOLOGY RESEARCH, 2018